MedTrace Logo

Combination Therapy Prevents the Relapse of RA

NCT02320630 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-06-22

No results posted yet for this study

Summary

This trial aims to compare the cost effective and effect of preventing recurrence by different treatment of TFP and HCQ combined SSZ for remittent RA.

Conditions

  • Recurrence (Disease Attribute)

Interventions

DRUG

Entanercept

Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).

DRUG

HCQ

Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).

DRUG

MTX

MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Peking University Shougang Hospital

    collaborator OTHER

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-02-28
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02320630 on ClinicalTrials.gov